Salipro Biotech AB published a study revealing how a disease-causing mutation disrupts an essential lipid interaction required for normal Na⁺/K⁺ pump function using Salipro® cryo-electron microscopy.

Making the undruggable druggable. Salipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. Headquartered in Stockholm, Sweden, the company collaborates with global pharma and biotech companies to accelerate the discovery of novel drugs. For our own pipeline, we are striving to develop drugs toward targets that no one could access before. The majority of drug targets are so-called membrane proteins; however, these targets are inherently unstable and challenging to investigate. Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design.